
    
      A Multicenter, Randomized, Double-blind, Parallel Design, Phase III Clinical Trial to
      Evaluate the Efficacy and Safety of CKD-390 tablet and VireadÂ® tablet in Chronic hepatitis B
      Patients Subjects will receive either a single oral dose of the test formulation(CKD-390) or
      a oral dose of the reference formulation(viread).
    
  